Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01770600 |
Recruitment Status :
Withdrawn
(never initiated, did different study)
First Posted : January 18, 2013
Last Update Posted : May 28, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Impulsivity Active Suicidal Ideation Depression | Other: placebo Drug: Riperidone | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Assessment and Treatment of Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression. |
Study Start Date : | April 2010 |
Actual Primary Completion Date : | September 2013 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Risperidone
Administer pill of risperidone 1 mg once a day by mouth for 5 days.
|
Drug: Riperidone
1 mg risperidone administered orally for 5 days
Other Name: risperdal |
Placebo Comparator: Placebo
Administer pill of placebo once a day by mouth for 5 days.
|
Other: placebo
placebo pill administered daily for 5 days |
- Decrease in depression symptoms [ Time Frame: baseline to 5 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 64 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age : 19-64
- Suicidality score of > 4 on Montgomery-Asberg Depression Rating Scale (MADRS)
Exclusion Criteria:
- pregnant,
- medically unstable,
- history of schizophrenia,
- schizoaffective disorder,
- bipolar disorder,
- psychosis NOS,
- urine drug screen positive for cocaine,
- marijuana or amphetamines,
- withdrawal from opiates,
- benzodiazepines or alcohol,
- currently on antipsychotic drug therapy. Also excluded are those subjects who require the use of mood stabilizers or antipsychotics.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01770600
United States, Alabama | |
University of Alabama Birmingham | |
Birmingham, Alabama, United States, 35294 |
Principal Investigator: | Cheryl B McCullumsmith, MD PhD | University of Alabama at Birmingham |
Responsible Party: | Cheryl McCullumsmith, Division Director, Hospital Psychiatry, University of Alabama at Birmingham |
ClinicalTrials.gov Identifier: | NCT01770600 |
Other Study ID Numbers: |
F1003310002 |
First Posted: | January 18, 2013 Key Record Dates |
Last Update Posted: | May 28, 2015 |
Last Verified: | May 2015 |
Age 19 to 64 Medically stable No current or history of psychosis No alcohol or benzodiazepine withdrawal |
Depression Depressive Disorder Suicidal Ideation Impulsive Behavior Behavioral Symptoms Mood Disorders Mental Disorders Suicide Self-Injurious Behavior Risperidone Serotonin Antagonists |
Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Dopamine Antagonists Dopamine Agents |